Machine Learning-Based Prediction of Treatment Response to Vitamin D3 in Adolescents and Young Adults with Inflammatory Bowel Disease: A Prospective, Open-Label, Alternation-Based Comparative Study
Authors:
- Marina Adriana MercioniMMMarina Adriana Mercioni
- Adrian GoldișAGAdrian Goldiș
- Nina HolbanNHNina Holban
- Mihai Vasile PopescuMPMihai Vasile Popescu
- Radu DragomirRDRadu Dragomir
- Christian GoldișCGChristian Goldiș
- Bianca BeleiBBBianca Belei
- Ileana EnatescuIEIleana Enatescu
- Roxana FolescuRFRoxana Folescu
- Laura OlariuLOLaura Olariu
- Oana BeleiOBOana Belei
Open Access
- 12 July 2026
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 14 (7) , 1563
Abstract
Background: Chronic inflammatory bowel diseases (IBDs), specifically Crohn’s disease and ulcerative colitis, present substantial clinical challenges characterized by a relapsing-remitting course. These conditions often lead to serious complications and significantly impair nutritional status, physical development, and overall quality of life. Methods: This unicentric, prospective, open-label, alternation-based comparative study investigated the efficacy of vitamin D3 supplementation in adolescents with IBD. Patients aged 15–25 years were randomly assigned to receive either 1000 IU/day or 2000 IU/day of cholecalciferol for 6 months as an adjuvant to standard care. Eighty patients completed the study. Results: By month 6, remission was achieved in 52.5% of patients receiving 1000 IU/day (Group A) and 87.5% of those receiving 2000 IU/day (Group B). Significant differences were observed between groups regarding disease activity (p = 0.007), C-reactive protein levels (30.17 ± 15.74 mg/L vs. 62.82 ± 37.14 mg/L; p < 0.001), and fecal calprotectin levels. Conclusions: The machine learning models demonstrated consistent performance in assessing inflammatory indicators, with a weighted average recall exceeding 72% (Random Forest: 82.50%). No adverse effects were reported. Supplementation with 2000 IU/day of vitamin D3 for 6 months was associated with more favorable clinical and biochemical outcomes than 1000 IU/day in this single-center open-label study as an adjunct to standard treatment in adolescents and young adults with IBD. The results suggest that higher doses of vitamin D may be beneficial in achieving remission and reducing systemic inflammation.Keywords
Funding Information
- “Victor Babes” University of Medicine and Pharmacy Timisoara
This publication has 38 references indexed in Scilit:
- Machine learning models for predicting pharmacokinetics and pharmacodynamics: A step toward personalized dosingJournal of Holistic Integrative Pharmacy, 2026
- Identifying key clinical and biochemical predictors of treatment outcomes in inflammatory bowel disease: a real-world evidence studyScientific Reports, 2025
- Medication-Related Impacts on Pediatric Bone HealthJournal of the Pediatric Orthopaedic Society of North America, 2025
- Multi-hop graph structural modeling for cancer-related circRNA-miRNA interaction predictionPattern Recognition, 2025
- Integrating QSP and ML to Facilitate Drug Development and Personalized Medicine2025
- Daily or intermittent vitamin D supplementation in patients with or at risk of osteoporosis: Position statement from the GRIOJoint Bone Spine, 2025
- Recent advances of Transformers in medical image analysis: A comprehensive reviewMedComm – Future Medicine, 2023
- Vitamin D therapy in pediatric patients with inflammatory bowel disease: a systematic review and meta-analysisWorld Journal of Pediatrics, 2022
- Impact of three different daily doses of vitamin D3supplementation in healthy schoolchildren and adolescents from North India: a single-blind prospective randomised clinical trialBritish Journal of Nutrition, 2019
- 25-Hydroxyvitamin D Concentrations in Children with Crohn's Disease Supplemented with Either 2000 or 400 IU Daily for 6 Months: A Randomized Controlled StudyThe Journal of Pediatrics, 2014